This is consistent with our strategy to participate in the generic market for Pfizer products that become subject to generic competition.

We've got a need to acquire products in the near term with all our patent expirations,

it's got to be consistent with our overall strategy and two, is there value in it?

We are early in the process but there is a high level of interest from a number of parties.

An important component of the reorganization is the additional resources and more intense focus we're bringing to the U.S. market because of the size and critical importance of the U.S. to our business.

The report focuses on prices paid by consumers without insurance and in doing so excludes manufacturer rebates or discounts.